| scholarly article | Q13442814 |
| P2093 | author name string | Xia Liu | |
| Dan Xu | |||
| Cheng-Kui Qu | |||
| Wen-Mei Yu | |||
| Stanton L Gerson | |||
| Caiying Guo | |||
| Howard J Meyerson | |||
| P2860 | cites work | Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome | Q24291893 |
| Spatial constraints on the recognition of phosphoproteins by the tandem SH2 domains of the phosphatase SH-PTP2 | Q24314461 | ||
| Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease | Q24540529 | ||
| Protein-tyrosine-phosphatase SHPTP2 couples platelet-derived growth factor receptor beta to Ras | Q24564495 | ||
| Crystal structure of the tyrosine phosphatase SHP-2 | Q27748898 | ||
| The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling | Q28182148 | ||
| PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects | Q28288812 | ||
| Cell-cycle checkpoints and cancer | Q28293996 | ||
| Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia | Q28298677 | ||
| Nf1 and Gmcsf interact in myeloid leukemogenesis | Q28507018 | ||
| Spatial and temporal patterns of ERK signaling during mouse embryogenesis | Q28594004 | ||
| Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia | Q44775999 | ||
| PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group | Q45073102 | ||
| Effects of a leukemia-associated gain-of-function mutation of SHP-2 phosphatase on interleukin-3 signaling | Q46863352 | ||
| An Shp2/SFK/Ras/Erk signaling pathway controls trophoblast stem cell survival | Q46975224 | ||
| Maintaining the ribosomal reading frame: the influence of the E site during translational regulation of release factor 2. | Q47226693 | ||
| Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. | Q47597394 | ||
| Structure and specificity of the SH2 domain | Q47846335 | ||
| TEL-AML1 Corrupts Hematopoietic Stem Cells to Persist in the Bone Marrow and Initiate Leukemia | Q57514984 | ||
| Modeling of C/EBPα Mutant Acute Myeloid Leukemia Reveals a Common Expression Signature of Committed Myeloid Leukemia-Initiating Cells | Q57615422 | ||
| PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention | Q59067116 | ||
| Lineage infidelity in acute leukemia | Q70429882 | ||
| MLL-GAS7 transforms multipotent hematopoietic progenitors and induces mixed lineage leukemias in mice | Q73086909 | ||
| Hematopoietic stem cell quiescence maintained by p21cip1/waf1 | Q73532192 | ||
| Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation | Q28594140 | ||
| Protein tyrosine phosphatases in the JAK/STAT pathway | Q28646447 | ||
| Inducible gene targeting in mice | Q29614544 | ||
| Protein tyrosine phosphatases: from genes, to function, to disease | Q29614826 | ||
| SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells | Q29615006 | ||
| A highly efficient recombineering-based method for generating conditional knockout mutations | Q29615157 | ||
| FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress | Q29615562 | ||
| Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells | Q29616552 | ||
| Chromosomal passengers: conducting cell division | Q29620468 | ||
| Requirement of Shp-2 tyrosine phosphatase in lymphoid and hematopoietic cell development | Q31835063 | ||
| Flow-cytometric phosphoprotein analysis reveals agonist and temporal differences in responses of murine hematopoietic stem/progenitor cells | Q33385651 | ||
| Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation | Q33732463 | ||
| Biased suppression of hematopoiesis and multiple developmental defects in chimeric mice containing Shp-2 mutant cells | Q33781066 | ||
| Abnormal mesoderm patterning in mouse embryos mutant for the SH2 tyrosine phosphatase Shp-2. | Q33886525 | ||
| Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems | Q34292599 | ||
| A germline gain-of-function mutation in Ptpn11 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hematopoietic stem cells | Q34310556 | ||
| Chromosome segregation and genomic stability | Q34326891 | ||
| Wnt signaling in the niche enforces hematopoietic stem cell quiescence and is necessary to preserve self-renewal in vivo. | Q34346883 | ||
| Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors | Q34641731 | ||
| Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells | Q34923711 | ||
| Kit-Shp2-Kit signaling acts to maintain a functional hematopoietic stem and progenitor cell pool | Q35029942 | ||
| Genetic evidence that Shp-2 tyrosine phosphatase is a signal enhancer of the epidermal growth factor receptor in mammals | Q35554092 | ||
| Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor | Q35847470 | ||
| Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells | Q35847802 | ||
| The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease | Q35847884 | ||
| Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines | Q36400929 | ||
| A deletion mutation in the SH2-N domain of Shp-2 severely suppresses hematopoietic cell development | Q36572223 | ||
| A new function for a phosphotyrosine phosphatase: linking GRB2-Sos to a receptor tyrosine kinase | Q36643931 | ||
| The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders | Q37159467 | ||
| Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis | Q37176577 | ||
| Unique and independent roles for MLL in adult hematopoietic stem cells and progenitors | Q39997748 | ||
| Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation | Q40587895 | ||
| Catalytic-dependent and -independent roles of SHP-2 tyrosine phosphatase in interleukin-3 signaling | Q40637759 | ||
| Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2. | Q41743522 | ||
| Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes | Q42480603 | ||
| Blocking the function of tyrosine phosphatase SHP-2 by targeting its Src homology 2 domains | Q42798239 | ||
| Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia | Q44419404 | ||
| ZIP codes for delivering SH2 domains | Q44616219 | ||
| Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis | Q44673842 | ||
| Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. | Q44760563 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1977-1988 | |
| P577 | publication date | 2011-09-19 | |
| P1433 | published in | Journal of Experimental Medicine | Q3186912 |
| P1476 | title | Non-lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells | |
| P478 | volume | 208 |
| Q41660964 | Aberrant Signaling Pathways in T-Cell Acute Lymphoblastic Leukemia |
| Q34722748 | Activating mutations in protein tyrosine phosphatase Ptpn11 (Shp2) enhance reactive oxygen species production that contributes to myeloproliferative disorder |
| Q50921811 | Azacitidine and Sorafenib Therapy in a Pediatric Patient With Refractory Acute Myeloid Leukemia With Monosomy 7 and Somatic PTPN11 Mutation. |
| Q51818284 | CCL3 is a key mediator for the leukemogenic effect of Ptpn11-activating mutations in the stem-cell microenvironment. |
| Q41522951 | Cancer: Bad neighbours cause bad blood |
| Q34056395 | Chromosome instability underlies hematopoietic stem cell dysfunction and lymphoid neoplasia associated with impaired Fbw7-mediated cyclin E regulation |
| Q53233871 | Clinical course of juvenile myelomonocytic leukemia in the blast crisis phase treated by acute myeloid leukemia-oriented chemotherapy and allogeneic hematopoietic stem cell transplantation. |
| Q90172838 | Critical role of ASCT2-mediated amino acid metabolism in promoting leukaemia development and progression |
| Q42380920 | DPP4 truncated GM-CSF and IL-3 manifest distinct receptor-binding and regulatory functions compared with their full-length forms. |
| Q38032488 | Dual faces of SH2-containing protein-tyrosine phosphatase Shp2/PTPN11 in tumorigenesis |
| Q38126465 | Engineering subtle targeted mutations into the mouse genome |
| Q47955988 | Gain-of-function mutation in PTPN11 in histiocytic sarcomas of Bernese Mountain Dogs. |
| Q52646137 | Gain-of-function mutations in the gene encoding the tyrosine phosphatase SHP2 induce hydrocephalus in a catalytically dependent manner. |
| Q36551546 | Gain-of-function mutations of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage-induced malignancies |
| Q41407670 | Genetic mutational profiling analysis of T cell acute lymphoblastic leukemia reveal mutant FBXW7 as a prognostic indicator for inferior survival |
| Q55101110 | Hematopoietic-restricted Ptpn11E76K reveals indolent MPN progression in mice. |
| Q34155125 | Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11). |
| Q37696377 | Impact of age on the survival of pediatric leukemia: an analysis of 15083 children in the SEER database |
| Q37150984 | Induction of a tumor-associated activating mutation in protein tyrosine phosphatase Ptpn11 (Shp2) enhances mitochondrial metabolism, leading to oxidative stress and senescence |
| Q90341588 | Inhibition of Inflammatory Signaling in Tet2 Mutant Preleukemic Cells Mitigates Stress-Induced Abnormalities and Clonal Hematopoiesis |
| Q33774488 | Inhibition of the Gab2/PI3K/mTOR signaling ameliorates myeloid malignancy caused by Ptpn11 (Shp2) gain-of-function mutations |
| Q37653117 | Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment |
| Q35308167 | Leukemogenic Ptpn11 allele causes defective erythropoiesis in mice |
| Q38504989 | Mechanisms and clinical applications of chromosomal instability in lymphoid malignancy |
| Q36783485 | Metabolic regulation by the mitochondrial phosphatase PTPMT1 is required for hematopoietic stem cell differentiation |
| Q47104523 | Mice expressing KrasG12D in hematopoietic multipotent progenitor cells develop neonatal myeloid leukemia |
| Q35685296 | Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition |
| Q43133276 | Natural variant of the Helicobacter pylori CagA oncoprotein that lost the ability to interact with PAR1. |
| Q37166923 | New and Unexpected Biological Functions for the Src-Homology 2 Domain-Containing Phosphatase SHP-2 in the Gastrointestinal Tract |
| Q38123936 | New insights into pre-BCR and BCR signalling with relevance to B cell malignancies |
| Q39642260 | Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias. |
| Q47105237 | Pharmacologic inhibition of PI3K p110δ in mutant Shp2E76K-expressing mice |
| Q30525672 | Protein tyrosine phosphatase Shp2 (Ptpn11) plays an important role in maintenance of chromosome stability |
| Q92420783 | Ptpn21 Controls Hematopoietic Stem Cell Homeostasis and Biomechanics |
| Q38227885 | Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting |
| Q48103763 | Regulatory Mechanisms and Novel Therapeutic Targeting Strategies for Protein Tyrosine Phosphatases. |
| Q39184182 | Role of SHP2 in hematopoiesis and leukemogenesis |
| Q37662297 | SHP-2 phosphatase contributes to KRAS-driven intestinal oncogenesis but prevents colitis-associated cancer development |
| Q38694762 | SHP2 overexpression enhances the invasion and metastasis of ovarian cancer in vitro and in vivo |
| Q55488060 | SHP2-Mediated Signal Networks in Stem Cell Homeostasis and Dysfunction. |
| Q34009953 | SHP2E76K mutant promotes lung tumorigenesis in transgenic mice |
| Q35825659 | Shp2 function in hematopoietic stem cell biology and leukemogenesis |
| Q42532012 | Shp2 regulates leukemic stem cell frequency in MLL-rearranged acute myeloid leukemia |
| Q93239307 | Small Molecule Inhibitor that Stabilizes the Autoinhibited Conformation of the Oncogenic Tyrosine Phosphatase SHP2 |
| Q37161507 | Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies |
| Q90413960 | The Physiopathology of T- Cell Acute Lymphoblastic Leukemia: Focus on Molecular Aspects |
| Q58096686 | The tyrosine phosphatase Shp-2 confers resistance to colonic inflammation by driving goblet cell function and crypt regeneration |
| Q38712988 | Turning the tide in myelodysplastic/myeloproliferative neoplasms |
| Q47702122 | Yolk sac erythromyeloid progenitors expressing gain of function PTPN11 have functional features of JMML but are not sufficient to cause disease in mice. |
Search more.